VincentiF, et al.Belatacept and long-term outcomes in kidney transplantation. N Engl J Med2016; 374:333–343. doi: 10.1056/NEJMoa1506027. Erratum in: N Engl J Med 2016; 374:698. doi: 10.1056/NEJMx160003
VincentiF, Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 2016; 374:333–343. doi: 10.1056/NEJMoa1506027. Erratum in: N Engl J Med 2016; 374:698. doi: 10.1056/NEJMx16000310.1056/NEJMoa1506027)| false
FergusonR, Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011; 11:66–76. doi: 10.1111/j.1600-6143.2010.03338.x10.1111/j.1600-6143.2010.03338.x)| false
Most nephrologists learn early in their training that the most common immunosuppressant regimen for patients with a kidney transplant consists of a calcineurin inhibitor (CNI), mycophenolic acid (usually mycophenolate mofetil [MMF]), with or without some corticosteroid. Let’s take a quick look at two emerging outside-the-box immunosuppression tools.
The new kid on the block
CNIs have long been a thorn in kidney transplantation’s side—with a laundry list of adverse effects ranging from tremors to electrolyte disturbances to paradoxical nephrotoxicity (1). One newer drug that has provided a CNI-free option in some patients is belatacept (approved